Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.<\/p>\n
PubMed<\/a>\u00a0 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.<\/p>\n PubMed<\/a>\u00a0 Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409\u201336.<\/p>\n PubMed<\/a>\u00a0 Arcangeli G, Arcangeli S, Pinzi V, Benassi M, Benassi M, Strigari L. Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: a systematic review and metanalysis of randomized clinical trials. Cancer Treat Rev. 2018;70:22\u20139.<\/p>\n Article<\/a>\u00a0 Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464\u201373.<\/p>\n Article<\/a>\u00a0 Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104\u20139.<\/p>\n Article<\/a>\u00a0 Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys. 2001;49(1):51\u20139.<\/p>\n Article<\/a>\u00a0 Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, et al. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I\/II dose escalation study. Int J Radiat Oncol Biol Phys. 2010;76(1):14\u201322.<\/p>\n Article<\/a>\u00a0 Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309(24):2587\u201395.<\/p>\n Article<\/a>\u00a0 Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860\u20138.<\/p>\n Article<\/a>\u00a0 Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172\u20138.<\/p>\n Article<\/a>\u00a0 Incrocci L, De Vries K, Wortel R, Oomen E, Heemsbergen W, Pos F. OC-0272 hyprofractionated vs conventional radiotherapy for prostate cancer: 7 year results from the hyprotrial. Radiother Oncol. 2019;133:S135\u201336.<\/p>\n Article<\/a>\u00a0 Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360.<\/p>\n Article<\/a>\u00a0 Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol. 2017;35(17):1891\u20137.<\/p>\n Article<\/a>\u00a0 Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325\u201332.<\/p>\n Article<\/a>\u00a0 Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884\u201390.<\/p>\n Article<\/a>\u00a0 Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018;36(29):2943\u20139.<\/p>\n Article<\/a>\u00a0 Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16(3):274\u201383.<\/p>\n Article<\/a>\u00a0 Yu JB. Hypofractionated radiotherapy for prostate cancer: further evidence to tip the scales. J Clin Oncol. 2017;35(17):1867\u20139.<\/p>\n Article<\/a>\u00a0 Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data. JAMA. 2015;313(16):1657.<\/p>\n Article<\/a>\u00a0 Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387\u201387.<\/p>\n Article<\/a>\u00a0 Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol. 2019;201(3):528\u201334.<\/p>\n Article<\/a>\u00a0 Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136.<\/p>\n Article<\/a>\u00a0 Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014. https:\/\/doi.org\/10.1093\/jnci\/dju244<\/a>.<\/p>\n Article<\/a>\u00a0 Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132\u20138.<\/p>\n Article<\/a>\u00a0 LENT SOMA tables table of contents. Radiother Oncol. 1995;35(1):17\u201360.<\/p>\n Article<\/a>\u00a0 Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464\u201374.<\/p>\n Article<\/a>\u00a0 Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79(4):1013\u201321.<\/p>\n Article<\/a>\u00a0 Dearnaley DP, Griffin C, Syndikus I, Khoo V, Birtle AJ, Choudhury A, et al. Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK\/06\/016): update from the CHHiP trial. J Clin Oncol. 2020;38(6suppl):325\u201325.<\/p>\n Article<\/a>\u00a0 Syndikus I, Griffin C, Philipps L, Tree A, Khoo V, Birtle AJ, et al. 10-year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016). J Clin Oncol. 2023;41(6suppl):304\u201304.<\/p>\n Article<\/a>\u00a0 Karklelyte A, Valuckas KP, Griskevicius R, Janulionis E, Aleknavicius E. Acute toxicity and quality of life in high risk prostate cancer patients: updated results of randomized hypofractionation trial. Rep Pract Oncol Radiother. 2018;23(4):284\u20139.<\/p>\n Article<\/a>\u00a0 Niazi T, Nabid A, Malagon T, Bettahar R, Vincent L, Martin A-G, et al. Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the prostate cancer Study-5, a groupe de Radio-Oncologie G\u00e9nito-Urinaire de Quebec led phase 3 trial. Int J Radiat Oncol Biol Phys. 2024;118(1):52\u201362.<\/p>\n Article<\/a>\u00a0 Soni A, Jadhav GK, Manocha S, Chauhan S, Goswami B, Verma M. Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer. Rep Pract Oncol Radiother. 2022;27(6):1001\u20139.<\/p>\n Article<\/a>\u00a0 Viani GA, da Silva LBG, da Silva BB, Crempe YB, Martins VS, Ferrari RJR, et al. Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment. Radiat Oncol. 2013. https:\/\/doi.org\/10.1186\/1748-717X-8-94<\/a>.<\/p>\n Article<\/a>\u00a0 Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2011;81(5):1271\u20138.<\/p>\n Article<\/a>\u00a0 Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928\u201328.<\/p>\n Article<\/a>\u00a0 Sinzabakira F, Brand V, Heemsbergen WD, Incrocci L. Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: a systematic review and meta-analysis. Clin Transl Radiat Oncol. 2023. https:\/\/doi.org\/10.1016\/j.ctro.2023.100612<\/a>.<\/p>\n Article<\/a>\u00a0 Francolini G, Detti B, Becherini C, Caini S, Ingrosso G, Di Cataldo V et al. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature. Crit Rev Oncol\/Hematol 2021; 165.<\/p>\n Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124\u20139.<\/p>\n Article<\/a>\u00a0 Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Miller DC, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol. 2014;65(1):162\u20138.<\/p>\n Article<\/a>\u00a0 Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis. 2007;10(1):82\u20136.<\/p>\n Article<\/a>\u00a0 Peach MS, Showalter TN, Ohri N. Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. Prostate Cancer. 2015; 2015:1\u201311.<\/p>\n Carvalho IT, Baccaglini W, Claros OR, Chen FK, Kayano PP, Lemos GC, et al. Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis. Acta Oncol. 2018;57(8):1003\u201310.<\/p>\n Article<\/a>\u00a0 Yin ZZ, You JQ, Wang YY, Zhao JL, Jiang SP, Zhang XM, et al. Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from phase III randomized trials. Oncotargets Ther. 2019;12:1259\u201368.<\/p>\n Article<\/a>\u00a0 Baccaglini W, de Carvalho IT, Glina FPA, Pazeto CL, Marantes A, Nascimento M, et al. Radiotherapy-related toxicity for localized prostate cancer: meta-analysis comparing conventional or moderately hypofractionated vs. ultrahypofractionated protocols. Clin Transl Oncol. 2022;24(7):1425\u201339.<\/p>\n Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020:…\n","protected":false},"author":2,"featured_media":234533,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[3875,49,48,3877,111050,111052,3673,111053,84,82416,111054,3672,111049,32675,111051,82415],"class_list":["post-234532","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-biomedicine","tag-ca","tag-canada","tag-cancer-research","tag-conventionally-fractionated-radiotherapy","tag-gastrointestinal-toxicity","tag-general","tag-genitourinary-toxicity","tag-health","tag-health-promotion-and-disease-prevention","tag-localized-prostate-cancer","tag-medicine-public-health","tag-moderately-hypofractionated-radiotherapy","tag-oncology","tag-relapse-free-survival-over-five-years","tag-surgical-oncology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/234532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=234532"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/234532\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/234533"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=234532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=234532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=234532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}